Impact of thalidomide-based induction regimens on PBSC harvest in multiple myeloma patients

被引：0
|
作者：
Lanska, M. [1 ]
Maisnar, V. [1 ]
Radocha, J. [1 ]
Zak, P. [1 ]
Zavrelova, A. [1 ]
Blaha, M. [1 ]
Horacek, J. [1 ]
Doskocilova, K. [1 ]
Maly, J. [1 ]
机构：
[1] Teaching Hosp, Hradec Kralove, Czech Republic
来源：
BONE MARROW TRANSPLANTATION | 2010年 / 45卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S151 / S151
页数：1
相关论文
共 50 条
  • [31] Novel Induction Regimens in Multiple Myeloma
    Runcie, Karie D.
    Mark, Tomer M.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2015, 10 (04) : 388 - 394
  • [32] Novel Induction Regimens in Multiple Myeloma
    Karie D. Runcie
    Tomer M. Mark
    Current Hematologic Malignancy Reports, 2015, 10 : 388 - 394
  • [33] IMPACT OF INCIDENCE GAIN(1)(Q21) FOR RELAPSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE OR BORTEZOMIB-BASED REGIMENS
    Smetana, J.
    Berankova, K.
    Zaoralova, R.
    Nemec, P.
    Greslikova, H.
    Mikulasova, A.
    Zahradova, L.
    Almasi, M.
    Hajek, R.
    Kuglik, P.
    HAEMATOLOGICA, 2012, 97 : 596 - 596
  • [34] Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma
    Kaufman, Jonathan L.
    Gleason, Charise
    Heffner, Leonard
    Lonial, Sagar
    BLOOD, 2007, 110 (11) : 1055A - 1055A
  • [35] Gain 1q21 Versus Velcade- and Thalidomide-Based Regimens
    Nemec, P.
    Greslikova, H.
    Smetana, J.
    Zaoralova, R.
    Kupska, R.
    Berankova, K.
    Filkova, H.
    Kralova, D.
    Krejci, M.
    Pour, L.
    Zahradova, L.
    Sandecka, V.
    Adam, Z.
    Kuglik, P.
    Hajek, R.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S116 - S116
  • [36] Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen
    Szudy-Szczyrek, Aneta
    Mlak, Radoslaw
    Mielnik, Michal
    Szczyrek, Michal
    Nowaczynska, Aleksandra
    Homa-Mlak, Iwona
    Zmorzynski, Szymon
    Kusmierczuk, Kinga
    Sompor, Jacek
    Filip, Agata
    Maecka-Massalska, Teresa
    Hus, Marek
    ANNALS OF HEMATOLOGY, 2020, 99 (12) : 2881 - 2891
  • [37] Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen
    Aneta Szudy-Szczyrek
    Radosław Mlak
    Michał Mielnik
    Michał Szczyrek
    Aleksandra Nowaczyńska
    Iwona Homa-Mlak
    Szymon Zmorzyński
    Kinga Kuśmierczuk
    Jacek Sompor
    Agata Filip
    Teresa Małecka-Massalska
    Marek Hus
    Annals of Hematology, 2020, 99 : 2881 - 2891
  • [38] Predictive factors in peripheral blood stem cell (PBSC) harvest in multiple myeloma (MM) patients
    Worel, N
    Schlögl, E
    Rabitsch, W
    Kührer, I
    Greinix, HT
    Höcker, P
    BONE MARROW TRANSPLANTATION, 1998, 21 : S209 - S209
  • [39] Polymorphism of TNF-a Predicts Clinical Outcome in Multiple Myeloma Based on Thalidomide Regimens
    Du, J.
    Zhang, C.
    Jiang, H.
    Yuan, Z.
    Fu, W.
    Xiao, H.
    Hou, J.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S107 - S107
  • [40] Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review
    Kumar, Ambuj
    Hozo, Iztok
    Wheatley, Keath
    Djulbegovic, Benjamin
    AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (01) : 18 - 24
12345